Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

← catalyst calendar

NCT01905813

Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

121actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2013-06-30

actual

When the study began enrolling

Primary completion

2026-02-26

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-02-26

actual

The whole study's end, after follow-up

First posted

2013-07-23

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

B-cell Malignancies

Interventions

Drug: INCB040093
Drug: INCB040093 + itacitinib — also filed as itacitinib (INCB039110)

Primary outcome

what the primary-completion date above is the date OF

Safety and tolerability of INCB040093 as monotherapy and when given in combination with itacitinib as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events

measured Measured every 3 weeks until progression.

Publications

PMID 29695516 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed